La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

China Resources Double-Crane PharmaceuticalLtd Croissance future

Future contrôle des critères 1/6

China Resources Double-Crane PharmaceuticalLtd devrait augmenter ses bénéfices et son chiffre d'affaires de 11.1% et de 8.6% par an respectivement. Le BPA devrait croître de de 10.7% par an. Le rendement des capitaux propres devrait être 12.3% dans 3 ans.

Informations clés

13.8%

Taux de croissance des bénéfices

13.4%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	17.9%
Taux de croissance des recettes	9.7%
Rendement futur des capitaux propres	13.0%
Couverture par les analystes	Low
Dernière mise à jour	22 Aug 2024

Mises à jour récentes de la croissance future

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Recent updates

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Jul 16

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Mar 02

Prévisions de croissance des bénéfices et des revenus

SHSE:600062 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	13,386	2,037	N/A	2,383	2
12/31/2025	12,994	1,830	N/A	2,161	3
12/31/2024	11,714	1,633	N/A	1,884	3
3/31/2024	10,285	1,374	1,201	1,812	N/A
12/31/2023	10,222	1,333	1,026	1,631	N/A
9/30/2023	10,047	1,282	1,082	1,590	N/A
6/30/2023	9,983	1,223	922	1,404	N/A
3/31/2023	9,880	1,223	888	1,357	N/A
12/31/2022	9,625	1,180	890	1,416	N/A
9/30/2022	9,394	1,025	611	1,258	N/A
6/30/2022	9,392	1,078	720	1,337	N/A
3/31/2022	9,222	981	618	1,198	N/A
12/31/2021	9,112	936	849	1,341	N/A
9/30/2021	9,006	1,021	904	1,269	N/A
6/30/2021	8,987	1,046	964	1,328	N/A
3/31/2021	8,730	1,016	956	1,318	N/A
12/31/2020	8,504	1,005	1,012	1,360	N/A
9/30/2020	8,348	1,010	956	1,238	N/A
6/30/2020	8,663	971	1,068	1,323	N/A
3/31/2020	8,930	1,001	1,123	1,347	N/A
12/31/2019	9,381	1,055	1,198	1,440	N/A
9/30/2019	9,322	1,043	1,192	1,430	N/A
6/30/2019	9,003	1,024	1,195	1,428	N/A
3/31/2019	8,720	997	1,289	1,541	N/A
12/31/2018	8,225	969	1,240	1,469	N/A
9/30/2018	7,975	962	1,386	1,589	N/A
6/30/2018	7,434	905	1,211	1,406	N/A
3/31/2018	7,032	908	1,100	1,271	N/A
12/31/2017	6,422	843	N/A	1,187	N/A
9/30/2017	6,103	838	N/A	1,071	N/A
6/30/2017	5,725	801	N/A	1,107	N/A
3/31/2017	5,584	767	N/A	911	N/A
12/31/2016	5,495	714	N/A	771	N/A
9/30/2016	5,490	705	N/A	828	N/A
6/30/2016	5,414	684	N/A	775	N/A
3/31/2016	5,274	645	N/A	813	N/A
12/31/2015	5,138	661	N/A	701	N/A
9/30/2015	5,733	865	N/A	1,025	N/A
6/30/2015	5,562	832	N/A	1,016	N/A
3/31/2015	5,413	785	N/A	876	N/A
12/31/2014	5,153	737	N/A	929	N/A
9/30/2014	4,276	776	N/A	674	N/A
6/30/2014	5,184	845	N/A	539	N/A
3/31/2014	6,010	859	N/A	637	N/A
12/31/2013	6,835	871	N/A	546	N/A
9/30/2013	7,156	661	N/A	525	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 600062 ( 11.1% par an) est supérieure au taux d'épargne ( 2.9% ).

Bénéfices vs marché: Les bénéfices de 600062 ( 11.1% par an) devraient croître plus lentement que le marché CN ( 21.9% par an).

Croissance élevée des bénéfices: Les bénéfices de 600062 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 600062 ( 8.6% par an) devrait croître plus lentement que le marché de CN ( 13.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 600062 ( 8.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 600062 devrait être faible dans 3 ans ( 12.3 %).

China Resources Double-Crane PharmaceuticalLtd Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 26% to CN¥24.32

Price target increased to CN¥19.26

Recent updates

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Dividend of CN¥0.26 announced

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Now 20% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022)

Price target increased by 26% to CN¥24.32

Investor sentiment improves as stock rises 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥19.26

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021)

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million.

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019)

China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm

New 90-day low: CN¥11.83

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥11.90

New 90-day low: CN¥12.04

New 90-day low: CN¥12.51

Third quarter earnings released

New 90-day low: CN¥12.62

New 90-day low: CN¥12.77

Earnings released

New 90-day high - CN¥14.78

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance